Thermo Fisher to Distribute Chembio’s DPP COVID-19 System in US

By LabMedica International staff writers
Posted on 20 May 2020

Chembio Diagnostics, Inc. (Medford, NY, USA) has signed a multi-year, non‑exclusive agreement with Thermo Fisher Scientific Inc. (Waltham, MA, USA) to distribute Chembio’s DPP COVID-19 System in the US.

The DPP COVID‑19 System is a rapid serological test and analyzer that provides numerical readings for both IgM and IgG antibody levels within 15 minutes from a finger stick drop of blood. The DPP COVID‑19 System can include either Chembio’s Micro Reader 1 or Micro Reader 2 analyzer.

Image: The Chembio DPP platform (Photo courtesy of Chembio Diagnostics, Inc.)

“We are pleased to announce our strategic supplier partnership with the Fisher Healthcare channel, which will significantly increase our commercial footprint by providing access to thousands of hospital and physician office moderately complex labs across the country,” said Rick Eberly, Chembio’s President and Chief Executive Officer. “We have initiated a comprehensive training and marketing program for the Fisher Healthcare channel sales team, in order to expand the targeted coverage for this important segment of the market as soon as possible.”